NCT06268210进行中（未招募）2 期
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer (NeoLazer): a Phase II, Randomized, Multi-center Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 160
- 试验地点
- 1
- 主要终点
- Primary pathological response
研究概览
简要总结
In the randomized, multicenter Phase II clinical trial, we aim to evaluate the efficacy and safety of Lazertinib monotherapy or the combination of Lazertinib and cytotoxic chemotherapy as neoadjuvant therapy in patients with resectable, treatment-naive EGFR-mutant (exon 19 deletion or exon 21 L858R) non-small cell lung cancer, ranging from clinical stage IB to IIIB. The study is designed to assess the impact on pathological response, as well as effectiveness and safety considerations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At the time of providing consent, the patient must be an adult aged 19 years or older.
- •Must have histologically or cytologically confirmed completely resectable, non-squamous non-small cell lung cancer (according to AJCC 8th edition, stages IB-IIIB).
- •Complete surgical resection must be deemed feasible based on the investigator's determination and in accordance with local treatment practices. This decision must be verified through the collaboration of a multidisciplinary team, including surgical oncologists, medical oncologists, and radiation oncologists. (Methods of surgical resection: either lobectomy or segmentectomy)
- •Documented presence of EGFR activating mutations (EGFR exon 19 deletion or L858R mutation).
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Adequate and normal organ and bone marrow function, defined as follows:
- •Hemoglobin: ≥9.0 g/dL Absolute neutrophil count: ≥1.5 × 10^9/L Platelet count: ≥100 × 10^9/L Serum bilirubin: ≤1.5 x upper limit of normal (ULN) ALT and AST: ≤2.5 x ULN Creatinine clearance: ≥50 ml/min or serum creatinine ≤1.5 × ULN
- •Life expectancy of more than 6 months.
- •Female patients must agree to use appropriate contraceptive methods, should not be breastfeeding, and if of childbearing potential, must have evidence of non-pregnancy through a negative pregnancy test prior to initiation. Effective contraception should be maintained for up to 3 months after the last dose of Lazertinib (6 months for Pemetrexed/Carboplatin).
- •Women over 50 years who have discontinued all exogenous hormone therapy and have been amenorrheic for at least 12 months, considered in a "postmenopausal" state.
- •Irreversible surgical infertility due to hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; tubal ligation is not allowed.
- •Women under 50 years should be considered in a postmenopausal state if they have discontinued all exogenous hormone therapy for at least 12 months, with LH and FSH levels within the postmenopausal range per the testing institution's criteria.
- •Male patients who have not undergone vasectomy must agree to barrier contraception, specifically condom use, and effective contraception and sperm donation are prohibited for up to 3 months after the last dose of Lazertinib (6 months for Pemetrexed/Carboplatin).
排除标准
- •If there is evidence of locally advanced and/or metastatic disease (Stage IIIC-IV).
- •Known positive status for human immunodeficiency virus (HIV).
- •Evidence of severe or uncontrolled active infections, including chronic active hepatitis B and/or C; patients with chronic hepatitis B virus (HBV) with low viral load (HBV DNA ≤ 500 IU/mL or ≤ 2500 copies/mL) can participate if appropriate antiviral therapy can be continued during the treatment period.
- •Evidence of severe or uncontrolled systemic diseases such as uncontrollable hypertension, active bleeding, etc.
- •History of solid organ transplantation.
- •History of interstitial lung disease (ILD) requiring steroid treatment or clinically active ILD.
- •History of malignancies other than non-small cell lung cancer within the past 3 years at the time of the first dose of the investigational drug (exceptions: treated cervical intraepithelial neoplasia, differentiated thyroid cancer without lymph node involvement, non-melanoma skin cancer).
- •Intractable nausea and vomiting, gastrointestinal disorders, or patients for whom oral administration is not feasible, and those deemed to have absorption disorders that may interfere with Lazertinib absorption, with the exception of cases where clinically significant absorption disorders are not present, as determined by the investigator, in patients who have undergone colon resection.
- •Pregnant or lactating women.
- •Any of the following cardiac criteria:
- •Average QT interval corrected for heart rate (QTcF) > 470 msec based on three electrocardiogram (ECG) measurements taken with the screening ECG equipment.
- •Clinically significant abnormalities in rhythm, conduction, or morphology at rest on ECG, such as complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval > 250 msec.
- •Clinically significant heart failure, congenital long QT syndrome, known concomitant drug administration that prolongs the QT interval, or any factors that increase the risk of QTc prolongation or arrhythmias, such as a family history of QTc prolongation or sudden death under the age of
- •Known hypersensitivity to the active or inactive ingredients of Lazertinib or drugs with a similar chemical structure or belonging to the same class.
- •If, in the investigator's judgment, a patient is unlikely to comply with the clinical trial procedures, restrictions, and requirements, and it is determined that the patient should not participate in the clinical trial.
- •Currently participating or planning to participate in any other interventional clinical trial excluding non-interventional clinical trials.
研究组 & 干预措施
Experimental
Experimental
Patients will receive a combination therapy of Lazertinib and Pemed-S + Carboplatin as neoadjuvant treatment before surgery, followed by post-surgery maintenance with Lazertinib at a dosage of 240 mg once daily for a duration of 3 years.
Dosages:
Lazertinib: 240 mg once daily (pre-/post-surgery for 3 years) Pemetrexed: 500 mg/m2 every 3 weeks (neoadjuvant therapy for 3 cycles) Carboplatin: AUC5 every 3 weeks (neoadjuvant therapy for 3 cycles)
干预措施: Lazertinib+Pemetrexed+Carboplatin (Drug)
Comparator
Active Comparator
Lazertinib will be administered at a dosage of 240 mg once daily, both before and after surgery, for a duration of 3 years.
干预措施: Lazertinib (Drug)
结局指标
主要结局
Primary pathological response
时间窗: After neo adjuvant treatment(3months)
Primary pathological response refers to the condition where the proportion of viable tumor cells is defined as 10% or less, indicating a substantial reduction in the survival of tumor cells.
次要结局
- Pathologic Complete Response(After neo adjuvant treatment(3months))
- Objective Response Rate(After surgery(3months))
- Event-Free Survival(End of trial(3years))
- Surgical Resection Methods (Segmentectomy or Lobectomy)(After radical surgery(3months))
- Overall Survival(End of trial(3years))
- Number of patients with Adverse events according to CTCAE v5.0(End of trial(3years))
- Disease-Free Survival(End of trial(3years))
研究者
Chang Gon Kim
Principal Investigator
Yonsei University
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric JunctionEsophageal CancerNCT06469060Shanghai Chest Hospital34
尚未招募
2 期
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLCNon-Small Cell Lung Cancer Stage IIIANCT04455594The First Affiliated Hospital of Guangzhou Medical University168
招募中
2 期
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung CancerNon-small Cell Lung Cancer Stage IIINCT04728724Shanghai Pulmonary Hospital, Shanghai, China100
进行中（未招募）
2 期
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)Resectable SarcomaNCT04968106Institut Bergonié66
已完成
2 期
Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal CancerRectal NeoplasmsNCT00421824Sanofi108